Presentation is loading. Please wait.

Presentation is loading. Please wait.

Journal of Thoracic Oncology

Published byRachel Skinner Modified over 5 years ago

Similar presentations

Presentation on theme: "Journal of Thoracic Oncology"— Presentation transcript:

1 Journal of Thoracic Oncology
Persistent Part-Solid Nodule in the Lung Represents Pulmonary Adenocarcinoma  Sang Hwan Lee, MD, Chang Min Park, MD, PhD, Jin Mo Goo, MD, Hyun Ju Lee, MD  Journal of Thoracic Oncology  Volume 6, Issue 3, (March 2011) DOI: /JTO.0b013e31820b9bd2 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Persistent part-solid nodule representing pulmonary adenocarcinoma in a 58-year-old woman. A, nonenhanced computed tomography (CT) scan of the chest shows a 20-mm nodule having peripheral ground-glass opacity portion and central solid portion, known as “part-solid nodule” in the right upper lobe. This lesion remained unchanged on follow-up CT taken 1month later. B, photomicrograph from lobectomy specimen reveals that this lesion is pulmonary adenocarcinoma with bronchioloalveolar carcinoma pattern (Hematoxylin-eosin stain, ×5). Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31820b9bd2) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Journal of Thoracic Oncology"

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer  Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,
Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD 
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground- glass attenuation on computed tomography  Shun-ichi Watanabe, MD,

Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground- glass attenuation on computed tomography  Shun-ichi Watanabe, MD,
Preoperative Localization of Lung Nodules With Fiducial Markers: Feasibility and Technical Considerations  Amita Sharma, MD, Shaunagh McDermott, MD, Douglas.

Preoperative Localization of Lung Nodules With Fiducial Markers: Feasibility and Technical Considerations  Amita Sharma, MD, Shaunagh McDermott, MD, Douglas.
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD 

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD 
Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P

Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.
David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F
Ashok K. Malani, MD, MS, Brian Olofsson, MD, David Debono, MD 

Ashok K. Malani, MD, MS, Brian Olofsson, MD, David Debono, MD 
Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma

Exogenous Lipoid Pneumonia Mimicking Multifocal Bronchogenic Carcinoma
Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,
Rapidly Progressive Diffuse Cystic Lesions as a Radiological Hallmark of Lung Adenocarcinoma  Jian Zhang, MD, Yi-Lin Zhao, MD, Ming-Xiang Ye, MD, Gang.

Rapidly Progressive Diffuse Cystic Lesions as a Radiological Hallmark of Lung Adenocarcinoma  Jian Zhang, MD, Yi-Lin Zhao, MD, Ming-Xiang Ye, MD, Gang.
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

Similar presentations

Ads by Google